Short-term evaluation of risk factor control and therapeutic prescription in secondary prevention of cardiovascular diseases;Evaluación a corto plazo del control de los factores de riesgo y de la prescripción terapéutica en prevención secundaria de enfermedad cardiovascular

Revista Clinica Espanola

Volumn 205, Issue 9, 2005, Pages 425-429

  Ciria de Pablo, C ^a,b   Pizarro Portillo, A ^a   Moreno Palanco, M A ^a   Sanchez Luis C ^a   Ibanez Sanz P ^a   Suarez Fernandez C ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b NONE   (Spain)

Author keywords

Cardiovascular diseases; Prevention; Risk factor

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES MELLITUS; DRUG CONTRAINDICATION; FEMALE; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRESCRIPTION; RISK ASSESSMENT; RISK REDUCTION; SECONDARY PREVENTION; STROKE;

EID: 27744503075     PISSN: 00142565     EISSN: None     Source Type: Journal    
DOI: 10.1157/13079070     Document Type: Article

References (22)

1. Llácer A, Fernández-Cuenca R. Mortalidad en España en 1999 y 2000. Boletín Epidemiológico Semanal. 2003; 11(10):109-20.
2. Samsa GP, Bian J, Lipscomb J, Matchar DB. Epidemiology of recurrent cerebral infarction: a medicare claims-based comparison of first and recurrent strokes on 2-year survival and cost. Stroke. 1999;30(2):338-49.
3. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J. 2003;24(17):1601-10.
4. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA. 2003;289(19):2560-72.
5. National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood colesterol in adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-97.
6. American Diabetes Association: Standards of Medical Care in Diabetes. Diabetes Care. 2004;27 Suppl 1:S15-35.
7. Straus SE, Majumdar SR, McAlister FA. New evidence for stroke prevention: scientific review. JAMA. 2002;288(11):1388-95.
8. MacWalter RS, Shirley CP. A Benefit-risk assessment of agents used in the secondary prevention of stroke. Drug Saf. 2002;25(13):943-63.
9. EUROASPIRE I and II group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet. 2001;357(9261):995-1001.
10. Velasco JA, Cosín J, López-Sendón JL, de Teresa E, de Oya M, Carrasco JL, et al. La prevención secundaria del infarto de miocardio en España. Estudio PREVESE. Rev Esp Cardiol. 1997;50(6):406-15.
11. Velasco JA, Cosín J, López-Sendón JL, de Teresa E, de Oya M, Sellers G. Nuevos datos sobre la prevención secundaria del infarto de miocardio en España. Resultados del estudio PREVESE II. Rev Esp Cardiol. 2002;55(8):801-9.
12. Filippi A, Bignamini AA, Sessa E, Samani F, Mazzaglia G. Secondary prevention of stroke in Italy: a cross-sectional survey in family practice. Stroke. 2003;34(4):1010-4.
13. Redfern J, McKevitt C, Rudd AG, Wolfe CD. Health care follow-up after stroke: opportunities for secondary prevention. Fam Pract. 2002;19(4):378-92.
14. Sappok T, Faulstich A, Stuckert E, Kruck H, Marx P, Koennecke HC. Compliance with secondary prevention of ischemic stroke: a prospective evaluation. Stroke. 2001;32(8):1884-9.
15. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens. 2003;21(11):1983-92.
16. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7-22.
17. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361 (9364):1149-58.
18. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342(3):145-53.
19. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358(9287):1033-41.
20. Fox KM; EURopean trial On reduction of cardiac events with perindopril in stable coronary artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362(9386):782-8.
21. Freemantle N, Cleland J, Young P, Mason J, Harrison J. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999;318(7200):1730-7.
22. Pi-Sunyer FX. Obesity: criteria and classification. Proc Nutr Soc. 2000; 59(4):505-9.